Sonnet Biotherapeutics' Previously Announced Interim Data From The Sb101 Trial Of SON-1010 (Il12- FHAB), Will Be Presented By Dr. Sant Chawla, A Key Opinion Leader In The Field Of Sarcoma Research, At The Upcoming Connective Tissue Oncology Society Annual
Portfolio Pulse from Benzinga Newsdesk
Sonnet Biotherapeutics has announced that interim data from the SB101 trial of SON-1010 (Il12- FHAB) will be presented by Dr. Sant Chawla, a key opinion leader in the field of sarcoma research, at the upcoming Connective Tissue Oncology Society Annual.

October 17, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet Biotherapeutics' interim data from the SB101 trial of SON-1010 will be presented at an upcoming conference, potentially influencing the company's stock.
The presentation of interim data from a trial is a significant event for a biotech company. If the data is positive, it could lead to increased investor confidence and a potential rise in the stock price. Conversely, if the data is negative, it could lead to a decrease in the stock price. Given that the data will be presented by a key opinion leader in the field, this event is highly relevant to Sonnet Biotherapeutics.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100